Hanmi Pharm, Stock Price Down 1.8% at This Hour... Institutional Investors Net Sell 38,614 Shares in Last 5 Days

Hanmi Pharm is trading at 354,000 KRW, down 1.8% from the previous day as of 11:31 AM on the 18th. The trading volume is 25,398 shares, which is 36.93% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.

On January 13, Minjeong Seon, a researcher at Hana Financial Investment, stated, "Among the new drugs developed by Hanmi Pharm in 2021, two are expected to receive approval from the US FDA. The PDUFA date for Oratox, developed by Athenex, remains February 28, and Rolontis, whose PDUFA date was postponed due to the COVID-19 pandemic, has not yet had a new PDUFA date assigned. However, if the inspection of the production plant, Pyeongtaek Bio New Plant, is completed, approval within the year is highly anticipated. The 2021 R&D outlook is promising." She set Hanmi Pharm's target price at 410,000 KRW.

Over the past five days, individual investors have net purchased 24,622 shares of Hanmi Pharm, while foreigners and institutions have net purchased 12,714 shares and net sold 38,614 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.